BioLineRx (BLRX) Shares Outstanding (Diluted Average) (2023 - 2025)

BioLineRx's Shares Outstanding (Diluted Average) history runs 3 years deep, the most recent figure standing at $2.5 billion for Q4 2025.

• In Q4 2025, Shares Outstanding (Diluted Average) rose 105.76% year-over-year to $2.5 billion; the TTM figure through Dec 2025 stood at $2.5 billion (up 105.76% YoY), while the FY2025 annual figure was $2.5 billion, up 105.76% from the prior year.
• Shares Outstanding (Diluted Average) was $2.5 billion for Q4 2025 at BioLineRx, up from $1.2 billion in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $2.5 billion in Q4 2025 to a low of $963.4 million in Q4 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $1.5 billion across 3 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) gained 24.37% in 2024, then jumped 105.76% in 2025.
• A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $963.4 million in 2023, then climbed by 24.37% to $1.2 billion in 2024, then jumped by 105.76% to $2.5 billion in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $2.5 billion (Q4 2025), $1.2 billion (Q4 2024), and $963.4 million (Q4 2023), per Business Quant data.